Transient prenatal ruxolitinib treatment suppresses astrogenesis during development and improves learning and memory in adult mice

Transient prenatal ruxolitinib treatment suppresses astrogenesis during development and improves learning and memory in adult mice

Show other versions (1)

Ruxolitinib is the first janus kinase 1 (JAK1) and JAK2 inhibitor that was approved by the United States Food and Drug Administration (FDA) agency for the treatment of myeloproliferative neoplasms. The drug targets the JAK/STAT signalling pathway, which is critical in regulating the gliogenesis proc...

Full description

Bibliographic Details
Main Authors: Abdullah, M.A (Author), Cheah, P.-S (Author), Habib, O. (Author), Hamzah, H. (Author), Hassan, Z. (Author), Lee, H.-C (Author), Leong, M.P.-Y (Author), Lim, S.-M (Author), Ling, K.-H (Author), Md Yusof, H. (Author), Mohd Moklas, M.A (Author), Nordin, N. (Author), Seth, E.A (Author), Vidyadaran, S. (Author), Zainal Abidin, S. (Author)
Format: Article
Language:English
Published: Nature Research 2021
Series:Scientific Reports
Online Access:View Fulltext in Publisher
View in Scopus

Internet

View Fulltext in Publisher
View in Scopus

Similar Items